Michael D. Roth, MD

Michael Roth, MD

Professor, Department of Medicine, Pulmonary and Critical Care Medicine and Molecular Toxicology
Vice Chairman for Research Compliance, Department of Medicine

Languages

English

Specialty

Pulmonary Disease

Education

Fellowship

Pulmonary Medicine, UCLA School of Medicine, 1986 - 1989

Internship

Internal Medicine, UCLA School of Medicine, 1983 - 1984

Degree

MD, UCLA School of Medicine, 1983

Residency

Internal Medicine, UCLA School of Medicine, 1984 - 1986

Board Certifications

Critical Care Medicine, American Board of Internal Medicine, 1989
Pulmonary Disease, American Board of Internal Medicine, 1988
Internal Medicine, American Board of Internal Medicine, 1986

Contact Information

Phone

(310) 206-7389 - Academic and research office
(310) 825-8061 - Pulmonary and Critical Care Medicine patient information and appointments
(310) 794-7333 - Lung Cancer Program patient appointments
(310) 825-6301 - Medical center page operator

Clinical Interests

Asthma, Chronic Cough, Emphysema, General Pulmonology, Lung Cancer and Chest Malignancies

Scientific Interests

Dr. Michael Roth's research focuses on understanding the development, regulation and function of dendritic cells and the generation of effective anti-cancer immunity. Several approaches are being investigated, including the development of immune stimulants that can be administered to cancer patients (GM-CSF, IL-4) to activate and expand dendritic cells in situ within their tissues and organs; the development of controlled release hydrogels for the local delivery of immunotherapeutic antibodies and drugs as a mechanism for improving their effectiveness while reducing their toxicity, and studies evaluating the impact that inhaled drugs of abuse (marijuana and cocaine) on the immune system. This research involves human in vitro studies, model systems and the translation of this basic research into new clinical trials in which immune-based therapy is being used to treat several types of cancer, including lung cancer and prostate cancer.

Highlighted Publications

Roth MD, Harui A. Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model. J Immunother Cancer. 2015 Apr 21;3:12. doi: 10.1186/s40425-015-0056-2. eCollection 2015.

Roth MD, Castaneda JT, Kiertscher SM. Exposure to Delta-9-Tetrahydrocannabinol Impairs the Differentiation of Human Monocyte-derived Dendritic Cells and their Capacity for T cell Activation. J Neuroimmune Pharmacol. 2015 Jun;10(2):333-43. doi: 10.1007/s11481-015-9587-z. Epub 2015 Jan 23.

Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, Tashkin DP, Goodglick L, Holmes EC, Cameron RB, Dubinett SM, Elashoff R, Szabo E, Elashoff D. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila). 2011 Jul;4(7):984-93. doi: 10.1158/1940-6207.CAPR-11-0078.

Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005 Aug 1;11(15):5515-25.

Roth MD, Gitlitz BJ, Kiertscher SM, Park AN, Mendenhall M, Moldawer N, Figlin RA. Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. Cancer Res. 2000 Apr 1;60(7):1934-41.